For instance, it has been discovered that the ACAT inhibitor avasimibe, the COX2 inhibitor celecoxib, and the specific EP4 antagonist E7046, when combined with PD-1 or CTLA-4 inhibitors, generate a synergistic anti-tumor immune response in mice tumor models [97,98]. Here, CTLA4 is linked to neoplasm.